psilocybin

colorful brain art model
Biotech

Reunion's psychedelic reduces postpartum depression in ph. 2

Reunion’s RE104 reduced the symptoms of postpregnancy depression in a phase 2 study, setting up the biotech to enter a late-stage trial next year.
James Waldron Aug 18, 2025 7:52am
compass map direction find trail north

Compass' psychedelic therapy wins ph. 3, investors unimpressed

Jun 23, 2025 8:05am
Withdraw cancel rip up application

Psyence walks away from acquisition of fellow psilocybin biotech

Oct 7, 2024 5:16am
magic mushroom

Psyence acquires fellow psilocybin biotech Clairvoyant

Sep 6, 2024 9:25am
treasure map compass

Compass tracks PTSD improvements in midphase psilocybin trial

May 8, 2024 8:07am
Graphic of a brain constructed out of money

Reunion nets $103M, one of the largest for a psychedelic biotech

May 2, 2024 6:30am